Lotus Pharmaceutical Co Ltd

Lotus Pharmaceutical Co Ltd has a debt-to-equity ratio of 2.35, indicating a relatively high level of leverage. The company's liquidity position is characterized as medium, with a current ratio of 1.57, suggesting it can cover its short-term obligations but with limited buffer. The company's free cash flow of 381.06 million TWD is modest compared to its operating cash flow of 7.48 billion TWD, indicating that capital expenditures are consuming a significant portion of operating cash. In terms of profitability, the company's return on equity (ROE) is 19.85%, which is strong and suggests efficient use of shareholders' equity to generate profits. However, its return on assets (ROA) is 4.45%, which is relatively low, indicating that the company is not utilizing its assets as effectively as it could be. The company's gross profit margin is 57.99% (11.91 billion TWD gross profit on 20.51 billion TWD revenue), which is a positive sign of cost control and pricing power. The company's revenue is concentrated in a single business segment, as disclosed in its financial statements, with no material geographic diversification reported. This lack of diversification could expose the company to regional economic or regulatory risks. The company's operating income of 5.83 billion TWD is derived primarily from its pharmaceutical product lines, with no significant revenue from services or other sources. Looking ahead, the company's growth trajectory is uncertain, as no specific revenue growth rates or outlooks are provided in the available data. However, the company's capital expenditures of -4.35 billion TWD suggest a significant investment in infrastructure or expansion, which could support future growth. The company's net income of 4.72 billion TWD indicates a profitable operation, but the extent to which this will translate into future earnings growth is unclear. The company's risk profile is characterized by a medium liquidity risk and a low dilution risk. The key risk flag is that the company's net cash is negative after subtracting total debt, which could limit its financial flexibility. The company's long-term debt of 55.93 billion TWD is a significant portion of its total liabilities, which could increase its financial risk in the event of rising interest rates or economic downturns. The company's dilution risk is low, as there is no indication of significant share issuance or dilution potential. Recent events and disclosures do not provide specific details on recent filings or transcripts, but the company's financial statements and analyst estimates suggest a mixed outlook. The mean price target of 360.50 TWD and the median price target of 341.00 TWD indicate a generally positive sentiment among analysts, with a range from 260.00 TWD to 500.00 TWD. The mean recommendation of 1.86 suggests a slight bias toward a buy rating, with three strong-buy ratings, two buy ratings, and two hold ratings.